Table 3.
Characteristics of individuals included in the meta-analysis replication stratified by study.
| Study Cohort | ||||||
|---|---|---|---|---|---|---|
| SAPPHIRE* (United States) (n = 1,761) |
SAGE (United States) (n = 1,200) |
GALA II (United States) (n = 1,477) |
SAGE (Canada) (n = 423) |
CAPPS (Canada) (n = 226) |
Hutterites (United States) (n = 680) |
|
| Age in years – mean ± SD (range) | 34.1 ± 14.1 (12–57) | 15.3 ± 5.7 (7–41) | 12.8 ± 3.3 (8–21) | 9.0 ± 0.5 (7–10) | 7.2 ± 0.2 (6–8) | 29.8 ± 16.7 (6–78) |
| Female – no. (%) | 1,117 (63.4) | 574 (47.8) | 727 (49.2) | 187 (44.2) | 101 (44.7) | 352 (51.8) |
| Race-ethnicity – no (%) | ||||||
| African American | 1,761 (100) | 1,200 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| African Caribbean | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| European American | 0 (0) | 0 (0) | 0 (0) | 423 (100) | 226 (100) | 680 (100) |
| Latino | 0 (0) | 0 (0) | 1,477 (100) | 0 (0) | 0 (0) | 0 (0) |
| History of Asthma | 1,427 (64.5) | 916 (76.3) | 856(58.0) | 157 (37.1) | 47 (20.8) | 153 (22.5) |
| Serum total IgE (IU/ml) – geometric mean ± geometric SD | 120.3 ± 4.5 | 119.1 ± 4.8 | 162.4 ± 5.0 | 8.3 ± 15.4 | 14.8 ± 14.96 | 23.8 ± 4.6 |
SAPPHIRE denotes Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity; SAGE (United States), Study of African Americans, Asthma, Genes & Environments; GALA II, Gene-Environments and Admixture in Latino Americans; SAGE (Canada), Study of Asthma Genes and the Environment; CAPPS, Canadian Asthma Primary Prevention Study; SD, standard deviation; IgE, immunoglobulin E; and IU/ml, international units per milliliter.
*
SAPPHIRE individuals in the replication set excluded those who were part of the discovery set.